Literatur
Alappan R, Buller GK, Perazella MA. Trimethoprim-sulfamethoxazole therapy in outpatients: is hyperkalemia a significant problem? Am J Nephrol 1999;19:389–94.
Antoniuóu T, Gomes T, Juurlink D. Trimethoprim-Sulfamethoxazole-induced Hyperkalemia in patients receiving inhibitors of the Renin-Angiotensin system. Arch Inter Med 2010; 170(12): 1045–49.
Antoniuóu T, Hollands S, Macdonald EM et al. Trimethoprim-sulfamethoxazole and risk of sudden death among patients taking spironolactone. CMAJ 2015;187(4):E138–43
Fralick M, Macdonald EM, Gomes T, Antoniou T et al Co-trimoxazole and sudden death in patients receiving inhibitors of renin angiotensin system: population based study. BMJ 2014 Oct 30;349:g 6196.
Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709–17.
Stellungnahme der EMA vom 11. April 2014: PRAC recommends against combined use of medicines affecting the renin-angiotensin (RAS) system (EMA/196502/2014)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schulte, C., Mitchell, A. Unerwünschte Arzneiwechselwirkungen. CV 15, 28–29 (2015). https://doi.org/10.1007/s15027-015-0597-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15027-015-0597-9